Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival

Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma’s investigational drug PB272 for the extended adjuvant treatment of breast cancer .

Source: uk.finance.yahoo.com

Comments are closed.